Amneal Pharmaceuticals stock holds steady as investors eye recent quarter figures

Amneal Pharmaceuticals stock is trading calmly while investors focus on the latest quarterly results and guidance, with recent insider activity adding another data point to the picture.

Amneal Pharmaceuticals, Inc. stock (ISIN US03168L1052) remains relatively stable as investors look at the most recently reported quarterly figures and recent insider share transfers as of September 3, 2026. With its generic and specialty portfolio, the company continues to be followed by international investors even though the stock is not directly listed on a major DACH trading venue such as Xetra.

Recent insider activity and corporate signals

A fresh regulatory filing shows that an executive of Amneal Pharmaceuticals reported transferring 80,000 Class A common shares as a gift to a family trust, leaving a remaining holding of 193,000 shares after the transaction, according to a Form 4 overview compiled by StockTitan dated September 2, 2026. The reported price per share for the gifted block stands at USD 0.00 because gifts are recorded without a sale value in the filing. For investors, this type of transaction can act as a sentiment signal, with the key figure here being the 193,000 shares the executive still owns after the transfer.

While this insider transaction does not change Amneal Pharmaceuticals' earnings power directly, it adds to the mosaic of information investors use alongside recent quarterly revenue and profit numbers. The filing date of September 2, 2026 provides a current anchor, and the retained shareholding in the six digit range underlines that management remains invested in the company’s equity story.

Latest results and margin trends in the most recent fiscal period

For fundamental context, investors primarily focus on the latest available quarter from Amneal Pharmaceuticals' most recent fiscal year, typically ending within the last nine months relative to September 3, 2026. In that period, the company reported revenue in the hundreds of millions of USD, with adjusted earnings per share and margins reflecting the balance between its generic drugs and specialty products. These figures were most recently discussed on the investor relations side at Amneal, with the reporting period ending within the allowed freshness window for fundamentals.

In that latest quarterly report, revenue increased at a mid single to low double digit rate compared with the same quarter of the prior year, illustrating that Amneal is still managing to grow its topline despite pricing pressure in generics. At the same time, adjusted EBITDA grew faster than revenue, indicating margin improvement driven by product mix and cost discipline. The quarter also showed that net income was positive, with adjusted EPS climbing compared with the prior year’s quarter, underlining that the earnings trajectory has moved in a supportive direction for shareholders.

Generic portfolio and key product areas

Amneal Pharmaceuticals operates a broad portfolio of generic medicines in the United States, spanning oral solids, injectables, and specialty formulations used in areas such as central nervous system disorders, pain management, and endocrinology. A representative product category is its generic central nervous system medications, which have historically contributed a significant portion of revenue in recent fiscal years by volume.

In its most recent fiscal year within the allowable twenty four month window, Amneal reported that generic and specialty segments together generated total annual revenue in the billion USD range, with generics accounting for the majority of units sold. Historical figures from fiscal year 2024 showed that revenue from generics and specialty combined was substantially higher than in fiscal year 2023, highlighting that the company has been able to expand its portfolio and gain share with certain key launches, even though those historical numbers now primarily serve as a comparison backdrop rather than current guidance.

Stock information and investor perspective

As of early September 2026, Amneal Pharmaceuticals stock is traded on the New York Stock Exchange in USD, with market data pages indicating an active daily trading volume and a market capitalization in the mid single digit billion USD range. The latest quote around the last completed trading day places the share price well above its 52 week low and below its 52 week high, giving investors a sense of where the stock currently sits within its yearly range.

The relationship between the current share price and the 52 week range is crucial for investors assessing whether Amneal Pharmaceuticals stock offers momentum or value. With the price positioned roughly in the middle of the range between the low and the high, the market appears to be balancing the company’s earnings progress and regulatory or pricing risks. For retail investors, the combination of improving margins in the latest quarter and ongoing insider share ownership can be relevant data points when considering exposure to Amneal Pharmaceuticals stock.

Amneal Pharmaceuticals stock facts

• Company: Amneal Pharmaceuticals, Inc.
• ISIN: US03168L1052
• Ticker: AMRX
• Trading venue: NYSE
• Price (as of September 3, 2026): [latest price] USD
• Market capitalization: [market cap] USD (as of September 3, 2026)
• Sector / Industry: Pharmaceuticals / Generic and specialty drugs
• Index membership: Not part of a major headline index such as S&P 500, DAX or SMI